00:13:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
BioPorto är verksamma inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.

Kalender

2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-04-04 Ordinarie utdelning BIOPOR 0.00 DKK
2022-04-01 Årsstämma 2022
2022-03-10 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-11-15 Extra Bolagsstämma 2021
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning BIOPOR 0.00 DKK
2021-04-29 Årsstämma 2021
2021-03-17 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-14 Årsstämma 2020
2020-03-20 Ordinarie utdelning BIOPOR 0.00 DKK
2020-03-11 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-03-19 Ordinarie utdelning BIOPOR 0.00 DKK
2019-03-18 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-16 Ordinarie utdelning BIOPOR 0.00 DKK
2018-04-13 Årsstämma 2018
2018-03-08 Bokslutskommuniké 2017
2017-11-07 Kvartalsrapport 2017-Q3
2017-05-04 Kvartalsrapport 2017-Q1
2017-04-24 Ordinarie utdelning BIOPOR 0.00 DKK
2017-04-21 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-03 Kvartalsrapport 2016-Q3
2016-08-04 Kvartalsrapport 2016-Q2
2016-05-04 Kvartalsrapport 2016-Q1
2016-04-15 Ordinarie utdelning BIOPOR 0.00 DKK
2016-04-14 Årsstämma 2016
2016-03-16 Bokslutskommuniké 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-10 Kvartalsrapport 2017-Q2
2015-08-07 Kvartalsrapport 2015-Q2
2015-05-05 Kvartalsrapport 2015-Q1
2015-04-13 Ordinarie utdelning BIOPOR 0.00 DKK
2015-04-10 Årsstämma 2015
2015-03-18 Bokslutskommuniké 2014
2014-04-11 Ordinarie utdelning BIOPOR 0.00 DKK
2013-04-17 Ordinarie utdelning BIOPOR 0.00 DKK
2012-04-18 Ordinarie utdelning BIOPOR 0.00 DKK
2012-04-17 Årsstämma 2012
2011-03-17 Ordinarie utdelning
2010-04-21 Ordinarie utdelning
2021-11-19 17:05:32

November 19, 2021
Announcement no. 23

In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 patients

In July 2021, BioPorto A/S (BioPorto) initiated a dialogue with the US Food and Drug Administration (FDA) on a potential Emergency Use Authorization (EUA) of an NGAL assay for use in predicting the need for renal replacement therapy in COVID-19 patients. The dialogue was based on results from an ELISA and dipstick study of NGAL to screen for renal failure in COVID-19 patients conducted by clinical researchers at Columbia University’s Irving Medical Center, reporting a 97% negative predictive value for the need of renal replacement therapy.

This week, the FDA provided guidance to all In-vitro Diagnostics manufacturers that the FDA will focus its reviews on at-home and point-of-care COVID-19 diagnostic tests, certain high-volume lab-based molecular COVID-19 tests from home collected specimens, and requests supported by US government stakeholders. Consistent with this communication, the FDA has informed BioPorto that it does not recommend submitting an EUA application. Based on this feedback, BioPorto has decided not to pursue an EUA for an NGAL assay with this application for COVID-19 patients.

“With the exciting data from Columbia University, we saw an interesting opportunity to use the study as a foundation for an EUA of an NGAL assay in screening patients for the need of renal replacement therapy in COVID-19 patients. As the FDA has now decided to prioritize other areas within COVID-19, we have decided to discontinue this path,” said Dr. Christopher Bird, Chief Medical Officer at BioPorto.

This announcement does not alter BioPorto’s financial guidance for 2021 as most recently presented in the Interim Report for Third Quarter 2021.

For further information, please contact:

Dr. Christopher Bird, Chief Medical Officer, BioPorto A/S, +1 858 868 1814
Tim Eriksen, Investor relations, BioPorto A/S, +45 61 68 77 79
Email: investor@bioporto.com

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].